Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the 7th Annual Evercore HealthCONx Conference. Jean-Pierre Sommadossi, CEO and Founder, along with the management team, will deliver a business update and participate in a fireside chat on December 4, 2024, at 9:35 a.m. ET. The presentation will be accessible via live webcast on the company's website and will remain available for at least 90 days after the event.
Atea Pharmaceuticals (Nasdaq: AVIR), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di terapie antivirali orali, ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore HealthCONx. Jean-Pierre Sommadossi, CEO e Fondatore, insieme al team di gestione, fornirà un aggiornamento aziendale e parteciperà a una chiacchierata informale il 4 dicembre 2024, alle 9:35 a.m. ET. La presentazione sarà accessibile tramite webcast dal vivo sul sito web dell'azienda e rimarrà disponibile per almeno 90 giorni dopo l'evento.
Atea Pharmaceuticals (Nasdaq: AVIR), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias antivirales orales, ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx. Jean-Pierre Sommadossi, CEO y Fundador, junto con el equipo de gestión, ofrecerá una actualización comercial y participará en una charla informal el 4 de diciembre de 2024, a las 9:35 a.m. ET. La presentación estará disponible a través de una transmisión web en vivo en el sitio web de la empresa y permanecerá accesible durante al menos 90 días después del evento.
Atea Pharmaceuticals (Nasdaq: AVIR)는 항바이러스 경구 치료제 개발에 중점을 둔 임상 단계의 생명공학 회사로, 제7회 Evercore HealthCONx 콘퍼런스에 참여한다고 발표했습니다. Jean-Pierre Sommadossi CEO 및 창립자와 경영팀은 2024년 12월 4일 오전 9시 35분 ET에 사업 업데이트를 제공하고 담소에 참여할 예정입니다. 발표 내용은 회사 웹사이트를 통해 실시간 웹 캐스트로 제공되며, 이벤트 후 최소 90일 동안 이용 가능합니다.
Atea Pharmaceuticals (Nasdaq: AVIR), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies antivirales orales, a annoncé sa participation à la 7ème Conférence Annuelle Evercore HealthCONx. Jean-Pierre Sommadossi, PDG et Fondateur, accompagné de l'équipe de direction, présentera une mise à jour de l'entreprise et participera à une discussion informelle le 4 décembre 2024 à 9h35 HE. La présentation sera accessible via un webcast en direct sur le site de l'entreprise et restera disponible pendant au moins 90 jours après l'événement.
Atea Pharmaceuticals (Nasdaq: AVIR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von oralen antiviralen Therapeutika konzentriert, hat seine Teilnahme an der 7. Jahrestagung Evercore HealthCONx bekannt gegeben. Jean-Pierre Sommadossi, CEO und Gründer, wird zusammen mit dem Management-Team am 4. Dezember 2024 um 9:35 Uhr ET ein Update zum Unternehmen geben und an einem informellen Gespräch teilnehmen. Die Präsentation wird live über Webcast auf der Unternehmenswebsite zugänglich sein und bleibt mindestens 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024 at 9:35 a.m. ET.
A live webcast of the presentation will be available here and on the Company’s website at https://ir.ateapharma.com/. An archived webcast will be available on Atea Pharmaceuticals’ website for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the anticipated date and time of the Company’s presentation at the conference. When used herein, words including “expects,” “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Will O’Connor
Precision AQ
212-362-1200
will.oconnor@precisionaq.com
FAQ
When is Atea Pharmaceuticals (AVIR) presenting at the Evercore HealthCONx Conference 2024?
How can I watch Atea Pharmaceuticals' (AVIR) presentation at the 2024 Evercore Conference?
How long will Atea Pharmaceuticals' (AVIR) Evercore Conference presentation recording be available?
